- Home
- MP vs VERA Comparison
MP vs VERA Comparison
Compare MP & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MP
- VERA
- Stock Information
- Founded
- MP 2017
- VERA 2016
- Country
- MP United States
- VERA United States
- Employees
- MP N/A
- VERA N/A
- Industry
- MP Metal Mining
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- MP Basic Materials
- VERA Health Care
- Exchange
- MP Nasdaq
- VERA Nasdaq
- Market Cap
- MP 2.7B
- VERA 2.7B
- IPO Year
- MP N/A
- VERA 2021
- Fundamental
- Price
- MP $20.96
- VERA $33.37
- Analyst Decision
- MP Buy
- VERA Buy
- Analyst Count
- MP 11
- VERA 8
- Target Price
- MP $21.55
- VERA $63.50
- AVG Volume (30 Days)
- MP 3.1M
- VERA 749.7K
- Earning Date
- MP 02-20-2025
- VERA 11-07-2024
- Dividend Yield
- MP N/A
- VERA N/A
- EPS Growth
- MP N/A
- VERA N/A
- EPS
- MP N/A
- VERA N/A
- Revenue
- MP $184,074,000.00
- VERA N/A
- Revenue This Year
- MP N/A
- VERA N/A
- Revenue Next Year
- MP $72.90
- VERA N/A
- P/E Ratio
- MP N/A
- VERA N/A
- Revenue Growth
- MP N/A
- VERA N/A
- 52 Week Low
- MP $10.02
- VERA $14.20
- 52 Week High
- MP $24.01
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- MP 61.51
- VERA 22.57
- Support Level
- MP $19.93
- VERA $31.77
- Resistance Level
- MP $21.14
- VERA $36.28
- Average True Range (ATR)
- MP 1.04
- VERA 2.18
- MACD
- MP 0.42
- VERA -0.86
- Stochastic Oscillator
- MP 90.91
- VERA 13.34
About MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.